Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Maternal cholestasis during pregnancy programs metabolic disease in offspring
Georgia Papacleovoulou, … , A.S. Knisely, Catherine Williamson
Georgia Papacleovoulou, … , A.S. Knisely, Catherine Williamson
Published June 24, 2013
Citation Information: J Clin Invest. 2013;123(7):3172-3181. https://doi.org/10.1172/JCI68927.
View: Text | PDF
Research Article

Maternal cholestasis during pregnancy programs metabolic disease in offspring

  • Text
  • PDF
Abstract

The intrauterine environment is a major contributor to increased rates of metabolic disease in adults. Intrahepatic cholestasis of pregnancy (ICP) is a liver disease of pregnancy that affects 0.5%–2% of pregnant women and is characterized by increased bile acid levels in the maternal serum. The influence of ICP on the metabolic health of offspring is unknown. We analyzed the Northern Finland birth cohort 1985–1986 database and found that 16-year-old children of mothers with ICP had altered lipid profiles. Males had increased BMI, and females exhibited increased waist and hip girth compared with the offspring of uncomplicated pregnancies. We further investigated the effect of maternal cholestasis on the metabolism of adult offspring in the mouse. Females from cholestatic mothers developed a severe obese, diabetic phenotype with hepatosteatosis following a Western diet, whereas matched mice not exposed to cholestasis in utero did not. Female littermates were susceptible to metabolic disease before dietary challenge. Human and mouse studies showed an accumulation of lipids in the fetoplacental unit and increased transplacental cholesterol transport in cholestatic pregnancy. We believe this is the first report showing that cholestatic pregnancy in the absence of altered maternal BMI or diabetes can program metabolic disease in the offspring.

Authors

Georgia Papacleovoulou, Shadi Abu-Hayyeh, Evanthia Nikolopoulou, Oscar Briz, Bryn M. Owen, Vanya Nikolova, Caroline Ovadia, Xiao Huang, Marja Vaarasmaki, Marc Baumann, Eugene Jansen, Christiane Albrecht, Marjo-Riitta Jarvelin, Jose J.G. Marin, A.S. Knisely, Catherine Williamson

×

Figure 1

Metabolic phenotype of 18-week-old female offspring.

Options: View larger image (or click on image) Download as PowerPoint
Metabolic phenotype of 18-week-old female offspring.
(A) Body weight fro...
(A) Body weight from the day of weaning to 18 weeks of age; n = 8 animals per group. Dashed line: time of initiation of the WD. (B) Glucose tolerance test; n = 8 animals per group. (C) Representative image of PAS- (upper panel) and toluidine blue–stained (lower panel) livers; n = 6 animals per group. Original magnification, ×20 and ×5 (insets). (D) Immunoblotting against hepatic AMPK and mTOR in pooled samples from 6 animals per group. (E) Insulin tolerance test and serum insulin measurements; n = 6 animals per group. (F) Representative pancreatic H&E-stained sections; n = 6 animals per group. Original magnification, ×20 and ×5 (insets). (G) Immunoblotting for hepatic IR-β in pooled protein samples from 6 animals per group. *P ≤ 0.05 for differences in offspring fed a different diet; #P ≤ 0.05 for differences in offspring exposed to a different intrauterine environment. NC NC, NC-fed offspring from NC-fed mothers; NC WD, WD-fed offspring from NC-fed mothers; CA NC, NC-fed offspring from CA-fed mothers; CA WD, WD-fed offspring from CA-fed mothers.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts